Fierce Biotech June 3, 2024
BD is stretching its reach in patient monitoring with the $4.2 billion purchase of Edwards Lifesciences’ connected care portfolio—including indwelling and non-invasive sensors for operating rooms and ICUs, as well as the digital infrastructure needed to analyze that data.
The deal claims the entirety of Edwards’ Critical Care group, including its about 4,500 employees, which was previously being set up for a spinoff into an independent company.
The business brought in over $900 million in revenue during 2023, with devices placed in more than 10,000 hospitals. The Irvine, California-based division will operate as a separate unit under BD’s Medical segment.
“We believe the combination unlocks multiple new avenues for growth and value creation through BD’s broad global footprint, increased...
Today's Sponsors
Today's Sponsor